GOLDEN, Colo., Nov. 29, 2022 /PRNewswire/ — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein-based assay for breast cancer, today announced that it has entered into definitive agreements with certain…
Related Articles
News
GHX Recognizes Advancement in Supply Chain Automation with 2024 Millennium Club Honorees
March 25, 2025
UCBN
News, Syndication
Comments Off on GHX Recognizes Advancement in Supply Chain Automation with 2024 Millennium Club Honorees
Celebrating Healthcare Industry Leaders for Transforming Supply Chain Efficiency with Automation LOUISVILLE, Colo., March 25, 2025 /PRNewswire/ — Global Healthcare Exchange (GHX) is proud to announce the 2024 Millennium Club honorees, recognizing 94 forward-thinking healthcare […]
News
Denver metro digital male fertility startup partners with Mark Cuban’ company
June 28, 2023
UCBN
News, Syndication
Comments Off on Denver metro digital male fertility startup partners with Mark Cuban’ company
A local startup focused on making male fertility and sexual health care more accessible announced on Wednesday a partnership with Mark Cuban’s pharmaceutical company. Click here to view original post
News
STAT+: A new mom’s illness led to the first diagnosis of a rare condition after childbirth
August 16, 2023
UCBN
News, Syndication
Comments Off on STAT+: A new mom’s illness led to the first diagnosis of a rare condition after childbirth
Figuring out the right medical diagnosis for patients can be a tricky process. The recent case of a woman who became sick with a life-threatening disease shortly after giving birth shows how many factors had […]
